Betrixaban is a direct oral factor Xa inhibitor anticoagulant used for extended venous thromboembolism prophylaxis in hospitalised, medically ill patients. Simson Pharma's Betrixaban reference standard and impurities support stability-indicating method development for this anticoagulant.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Betrixaban Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.